Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Cardiff Oncology, Inc.

CRDF · Nasdaq · CIK 0001213037 · Healthcare · Biotechnology

INSIDER SIGNAL

57.2 / 100

2 buyers · 4 purchase transaction lines · $1.1M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+18.2 / 25
Role+13.0 / 20
Recency+2.0 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Mohindru ManiChief Executive Officer
●●
PACE GARY WDirector
●●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION93%Largest buyer: PACE GARY W · $1.0M
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-06-18–2026-06-18

Roles in the peak window: Chief Executive Officer, Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

57.2 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 57.4
  2. 57.4
  3. 57.3
  4. 57.2
  5. 57.2

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

4Purchases
0Sales
0Other Form 4 lines
4SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-10.7%
3M
-20.0%
6M
-31.6%
12M
-54.6%

Volatility & liquidity

Volatility
99.7%
Beta
—
Avg daily value
USD 1.1M

Valuation

Market cap
USD 84.0M
P/E
—

Fundamentals

Profit margin
-7.7%
ROE
-0.1%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
12,073,948
Previous report
12,308,314
Avg daily volume
702,315
Days to cover
17.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-14PACE GARY WPurchase (P)Common Stock687,285USD 1.46USD 1,003,436SEC filing ↗
2026-07-14Mohindru ManiPurchase (P)Common Stock34,364USD 1.46USD 50,171SEC filing ↗
2026-06-18PACE GARY WPurchase (P)Common Stock30,000USD 1.22USD 36,600SEC filing ↗
2026-06-18Mohindru ManiPurchase (P)Common Stock24,703USD 1.21USD 29,891SEC filing ↗
2025-07-30PACE GARY WPurchase (P)Common Stock290,000USD 2.45USD 710,500SEC filing ↗
2024-12-18Levine James E.Purchase (P)Common Stock2,400USD 5.00USD 12,000SEC filing ↗
2024-12-17Levine James E.Purchase (P)Common Stock2,752USD 5.42USD 14,916SEC filing ↗
2024-12-16Levine James E.Purchase (P)Common Stock2,564USD 3.83USD 9,820SEC filing ↗
2024-12-12TANNENBAUM RENEE PPurchase (P)Common Stock10,000USD 3.42USD 34,200SEC filing ↗
2024-12-11PACE GARY WPurchase (P)Common Stock361,615USD 2.60USD 940,199SEC filing ↗
2023-12-19PACE GARY WPurchase (P)Common Stock30,000USD 1.37USD 41,100SEC filing ↗
2023-11-10PACE GARY WPurchase (P)Common Stock22,950USD 0.98USD 22,491SEC filing ↗
2022-11-25Erlander MarkPurchase (P)Common Stock10,000USD 1.43USD 14,300SEC filing ↗
2022-09-19White LalePurchase (P)Common Stock15,000USD 1.64USD 24,600SEC filing ↗
2022-09-16Armitage James OPurchase (P)Common Stock13,000USD 1.56USD 20,280SEC filing ↗

Form 4 evidence

4 transaction lines in the latest 365-day window; 61 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-14PACE GARY WPurchase (P)Common Stock687,285USD 1.46USD 1,003,436SEC filing ↗
2026-07-14Mohindru ManiPurchase (P)Common Stock34,364USD 1.46USD 50,171SEC filing ↗
2026-06-18PACE GARY WPurchase (P)Common Stock30,000USD 1.22USD 36,600SEC filing ↗
Show recent Form 4 evidence (4 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-14PACE GARY WPurchase (P)Common Stock687,285USD 1.46USD 1,003,436SEC filing ↗
2026-07-14Mohindru ManiPurchase (P)Common Stock34,364USD 1.46USD 50,171SEC filing ↗
2026-06-18PACE GARY WPurchase (P)Common Stock30,000USD 1.22USD 36,600SEC filing ↗
2026-06-18Mohindru ManiPurchase (P)Common Stock24,703USD 1.21USD 29,891SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCRDF
CIK0001213037
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history61 transaction lines from 2020-01-01 to 2026-07-14
50 P purchase lines · 1 S sale lines · 10 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.